StevenDMillerMD

PubMed

• Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.
  Littlejohn, J.E., Cao, X., Miller, S.D., Ozvaran, M.K., Jupiter, D., Zhang, L., Rodarte, C., Smythe, W.R.> ;Int J Cancer. 2008 Jul 1
• Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma.
  Rascoe, P.A., Cao, X., Daniel, J.C., Miller, S.D., Smythe, W.R.> ;J Thorac Cardiovasc Surg. 2005 Aug
• 2 citations
  Gene therapy for sarcoma utilizing adenoviral transfer of the β-glucuronidase and bax genes and an anthracyline prodrug
  Steven D. Miller, Imran Mohiuddin, Xiaobo X. Cao, Mustafa K. Ozvaran, Jonathan C. Daniel, W. Roy Smythe> ;The Journal of Surgical Research. 2004 Oct 1
• Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.
  Ozvaran, M.K., Cao, X.X., Miller, S.D., Monia, B.A., Hong, W.K., Smythe, W.R.> ;Mol Cancer Ther. 2004 May
• Complications in pediatric surgical oncology.
  Miller, S.D., Andrassy, R.J.> ;J Am Coll Surg. 2003 Nov
• Adenoviral transfer of mda-7 leads to BAX up-regulation and apoptosis in mesothelioma cells, and is abrogated by over-expression of BCL-XL.
  Cao, X.X., Mohuiddin, I., Chada, S., Mhashilkar, A.M., Ozvaran, M.K., McConkey, D.J., Miller, S.D., Daniel, J.C., Smythe, W.R.> ;Mol Med. 2002 Dec
• Join now to see all